A Senate committee today shined the spotlight on the wave of high and unexpected increases in prescription drug costs that puts an incredible financial strain on hospitals and health systems and threaten our ability to provide high quality care each and every day.

In a statement submitted to the committee’s hearing on drug prices, the AHA recommended Congress and the administration move quickly to take a number of steps that would increase competition, transparency, access and value, while fostering innovation.

The impact of skyrocketing drug prices goes far beyond hospitals’ and health systems’ budgets. Everyone eventually feels it, including patients, insurance companies, employers, the government and taxpayers. All of us. Even those who are healthy and medication-free pay more when drug prices outpace inflation through increased premiums, co-pays, deductibles and taxes. When drug companies put profits before patients, we all pay the price.

The women and men who work in America’s hospitals and health systems recognize the value of truly innovative, life-saving medicines as much as anyone. But a drug priced beyond our reach or a patient’s reach will not save anyone’s life.

Related News Articles

he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
The Centers for Medicare…
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as…
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market.